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E-mail: ian.alexander@health.nsw.gov.auIn early gene therapy trials for SCID-X1, usingg-retroviral vec-
tors, T cell leukemias developed in a subset of patients second-
ary to insertional proto-oncogene activation. In contrast, we
have reported development of T cell leukemias in SCID-X1
mice following lentivirus-mediated gene therapy independent
of insertional mutagenesis. A distinguishing feature in our
study was that only a proportion of transplanted gc-deﬁcient
progenitors were transduced and therefore competent for
reconstitution. We hypothesized that reconstitution of SCID-
X1 mice with limiting numbers of hematopoietic progenitors
might be a risk factor for lymphoid malignancy. To test
this hypothesis, in the absence of transduction, SCID-X1
mice were reconstituted with serially fewer wild-type hemato-
poietic progenitors. A robust inverse correlation between he-
matopoietic progenitor cell dose and T-lymphoid malignancy
was observed, with earlier disease onset at lower cell doses. Ma-
lignancies were of donor origin and carried activating Notch1
mutations. These ﬁndings align with emerging evidence that
thymocyte self-renewal induced by progenitor deprivation
carries an oncogenic risk that is modulated by intra-thymic
competition from differentiation-committed cells. Although
insertional proto-oncogene activation is required for the devel-
opment of malignancy in humans, failure of gc-deﬁcient thy-
mocytes to effectively compete with this at-risk cell population
may have also contributed to oncogenesis observed in early
SCID-X1 trials.
INTRODUCTION
Gene therapy for X-linked severe combined immunodeﬁciency
(SCID-X1) has been successfully employed in the clinic by resto-
ration of gc expression in bone-marrow-derived CD34+ cells using
integrating vectors.1,2 In the earliest studies, using conventional
g-retroviral vectors, robust immune reconstitution was observed inMolecula
This is an open access article under the CC BY-Nthe majority of infants, likely owing to the selective advantage of
the transduced progenitors. However, despite successful pheno-
typic correction, 25% of treated infants developed T cell acute
lymphoblastic leukemia (T-ALL) as a consequence of insertional
mutagenesis. Furthermore, patients acquired secondary genomic ab-
normalities including activating mutations in NOTCH1.3,4 Although
the role of insertional mutagenesis via the activation of proto-onco-
genes such as LMO2 has been clearly implicated in the development
of T-ALL in SCID-X1 patients following gene therapy, the absence of
adverse events in patients treated similarly for adenosine deaminase
deﬁciency (ADA-SCID), despite also exhibiting integrations near
these proto-oncogenes, remains incompletely understood.
We have previously developed a mouse model of lentivirus-mediated
correction of SCID-X1 and observed lymphoid malignancies.5
Crucially, the oncogenic events observed in mice receiving gene ther-
apy were not attributable to insertional mutagenesis, suggesting alter-
native mechanisms for genotoxic risk in this model. One signiﬁcant
difference between positive control SCID-X1 mice reconstituted
with wild-type hematopoietic progenitor cells and SCID-X1 mice
receiving gene therapy with an equivalent number of vector-exposed
gc-deﬁcient progenitor cells was the absolute number of cells received
that were competent for lymphoid reconstitution. The gene therapyr Therapy: Nucleic Acids Vol. 6 March 2017 ª 2016 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Molecular Therapy: Nucleic Acidsgroup received a lower dose on account of only a subset of vector-
exposed gc-deﬁcient cells being transduced. We therefore hypothe-
sized that reconstitution of SCID-X1 mice with limiting numbers of
hematopoietic progenitor cells might be a risk factor for lymphoid
malignancy.
In the current study, we sought to explore the relationship between
hematopoietic progenitor cell dose and the incidence of lymphoid
malignancy by transplanting sub-lethally irradiated gc/Rag/
mice with serially fewer wild-type Sca1+ progenitor cells, in
the absence of gene transfer. The progenitor cell doses examined
fell within a range that supported immunological reconstitution,
and the resultant lymphoid compartment sizes varied by no
more than 2-fold, despite up to 100-fold differences in hemato-
poietic progenitor cell dose. Of greatest interest, however, was the
observation of a robust inverse correlation between cell dose and
the incidence of T-lymphoid malignancy, with progressively
shorter disease latency at lower cell doses. All malignancies
were wild-type donor cell-derived and carried activating Notch1
mutations.
Replicative stress has been implicated in the development of B cell
leukemia in mice6 and is a plausible antecedent to T-lymphoid onco-
genesis in the current study. While encompassing this possibility,
our ﬁndings fall within a conceptual framework provided by recent
insights into murine thymocyte biology. Most notable among these
is the observation of sustained thymic output despite complete
T cell progenitor deprivation (thymus autonomy), with autonomous
T cell production being supported by induction of a thymocyte self-
renewal phenotype.7–10 This self-renewal phenotype, which arises
in the double-negative (DN) 3 thymic niche and can also be induced
by deliberate Lmo2 overexpression,11 appears to carry an inherent
risk of oncogenesis that is dependent upon acquisition of additional
genetic lesions, such as Notch1 mutations. Moreover, competition
from bone-marrow-derived progenitors has been shown to increase
the turnover of thymocytes with a self-renewal phenotype, thereby
reducing the probability of acquiring oncogenic mutations.10 Directly
relevant to the SCID-X1 phenotype is the inability of gc-deﬁcient
thymic progenitors to progress to the DN3 niche, thereby reducing
their ability to provide competition to gc-proﬁcient progenitors.9
Thus, data generated in our model are consistent with limiting thymic
precursor supply, not only inducing a self-renewal phenotype in the
murine thymus, but also simultaneously reducing competition in
the DN3 niche with a resultant cell dose-dependent increase in
oncogenic risk.
There is currently no evidence that limiting thymic precursor supply
is a risk factor for lymphoid malignancy in humans; nevertheless, the
possibility of cell competition acting as a tumor suppressor mecha-
nism in the human thymus following vector-mediated insertional
oncogene activation remains a compelling hypothesis. Coupled
with disease-speciﬁc differences in the progression of thymic precur-
sors through T cell ontogeny, this hypothesis has the potential to help
explain differing risks of oncogenesis.2 Molecular Therapy: Nucleic Acids Vol. 6 March 2017RESULTS
The Frequency of Lymphoid Malignancy Is Inversely
Proportional to the Wild-Type Progenitor Cell Dose Used to
Reconstitute SCID-X1 Mice
To explore the notion that limiting thymic precursor supply is a risk
factor for oncogenesis, sub-lethally irradiated gc/Rag2/ recipi-
ents were reconstituted with different doses of wild-type bone
marrow hematopoietic progenitor cells (Figure 1A). We chose to
use gc/Rag2/ recipients because IL2RG/ mice have been
shown to have a “leaky” T cell phenotype that manifests with age12
and would therefore not be suitable for longitudinal studies. Impor-
tantly, however, the donor cells were IL2RG/. To ensure all mice
received an equivalent cell dose, the total cell number was ﬁxed at
5  105 per recipient animal, and, at the lower cell doses, Sca1+ pro-
genitor cells from IL2RG/mice (gc null) were combined with those
expressing gc; 5 105 (high dose), 5 104 (mid dose) or 5 103 (low
dose), with the latter two doses representing a phenocopy of 10% and
1% gene transfer, respectively. In this model, only wild-type cells are
capable of progressing past the double-negative 2 (DN2) stage of
thymic development.
To investigate long-term oncogenic risk, mice reconstituted with a
high, mid, or low dose of gc-expressing progenitors were observed
for up to 18 months. Lymphoid malignancies were never observed
in mice receiving the high dose, consistent with our previous study5
but detected exclusively in animals from the mid- and low-dose
groups between 6.6 and 17.6months post-transplantation (Figure 1B).
The latency for oncogenesis was also signiﬁcantly longer in the mid-
dose group compared with low-dose group (12.8 ± 3.5 and 8.9 ±
1.4 months, respectively; p = 0.02). Of the 31 mice that had received
the mid cell dose, four developed malignancy, while the incidence of
malignancy was not signiﬁcantly greater than in mice transplanted
with the high dose of progenitors, the survival rate was decreased
(p = 0.03). In the low-dose group, both the incidence of malignancy
and malignancy-free survival rates were signiﬁcantly different when
compared with the high-dose group (p = 0.0017 and p = 0.0001,
respectively). Of interest, the rate of malignancy in mice transplanted
with the low dose of gc-expressing cells (33.3%) was similar to that
observed in our previous study (28.6%).5Phenotypic Characterization of Leukemic Clones
Necropsy showed hepatosplenomegaly with extensive blast inﬁltra-
tion, and histological analysis revealed marked disruption of tissue ar-
chitecture in the liver, spleen, thymus (Figure 1C), lung, and kidney
(data not shown). Interestingly, enlarged thymi containing malignant
cells were almost exclusively present in mice transplanted with the
lowest dose of gc-expressing progenitors, which was in contrast to
mice that developed malignancy from the mid dose group, where
the thymus was small or, in most cases, not macroscopically visible
(Table 1).
Abnormal T cell populations in 12 of the 14 mice that developed ma-
lignancy were identiﬁed in the spleen, liver, thymus, bone marrow,
Figure 1. Incidence and Latency of Lymphoid Malignancies Observed under Conditions of Limiting Bone Marrow Progenitor Supply
(A) Experimental design. (B) Kaplan-Meier survival analysis at 18 months post-transplantation; animals receiving high, mid, and low wild-type gc-expressing cell doses are
indicated in blue, green, and red, respectively. (C) H&E staining of C57BL/6 control (top panels) or malignant samples from an animal receiving the low-dose of gc-expressing
progenitors (bottom panels, m209). Scale bar, 100 mm.
www.moleculartherapy.organd peripheral blood. White blood cell counts were also elevated in
these animals. The phenotypes of these tumors were diverse, with
cells expressing immature, mature, and atypical combinations of sur-
face markers (Table 1). In addition, two of the 14 malignancies
(14.3%) did not express the T cell markers CD3, CD4, or CD8 and
were B220 positive (m249 and m250).
Limiting Thymic Precursor Supply Did Not Prevent
Reconstitution of the Immunological Compartment
Peripheral blood assessed at 6 (data not shown) and 16 weeks post-
transplantation (Figure 2A) demonstrated lymphoid reconstitution
with all three doses, with T, B, and natural killer (NK) cell compart-
ments observed at the expected ratios. Lymphoid reconstitution for
mice receiving the mid dose of gc-expressing cells was only approx-
imately half (47%) that of animals receiving the high cell dose, despite
receiving 10-fold fewer gc-expressing cells. For mice receiving the
lowest dose of gc-expressing cells, lymphoid reconstitution was com-
parable to that of mice receiving the mid dose, and when compared
to mice receiving the high dose of wild-type cells (i.e., 100-fold
more gc-expressing cells), the lymphoid compartment was reduced
to only 43%.
The level of bonemarrow chimerism inmice reconstituted with either
the high or low dose of wild-type (CD45.1 positive) progenitors was
determined by ﬂow cytometry. The contribution of wild-type cells
was found to be 64.9% ± 3.0% (n = 8) in the high-dose group, indi-
cating that the majority of cells engrafted in the bone marrow were
derived from the wild-type gc-expressing progenitors. For animals
transplanted with the low dose of wild-type cells, the contributionwas 3.4% ± 0.3% (n = 7), consistent with only 1% of the transplanted
cells expressing gc.
T Cell Receptor Diversity Is Maintained under Conditions of
Limiting Thymic Precursor Supply
To determine whether T cell receptor (TCR) diversity was affected by
limiting thymic precursor supply, TCR Vb repertoire and spectratype
analyses (on selected highly expressed TCR Vb families) were per-
formed at 15 weeks post-transplantation. Analysis of the TCR Vb
repertoire demonstrated that, for the majority of cases, both broad
representation of all Vb families and the percentage of each Vb family
was equivalent in peripheral blood samples taken frommice receiving
each of the three gc-expressing progenitor cell doses (Figure 2B).
Spectratype analysis revealed normal Gaussian distribution of peaks
in mice receiving the high and mid dose of gc-expressing progenitors
for the majority of TCRVb families investigated (Figure 2C). For mice
reconstituted with low cell numbers, the spectratypes appeared more
restricted for some TCR Vb families. The observation of a relatively
diverse TCR Vb repertoire for all cohorts is suggestive of increased
expansion of immature T cells at the low compared with the high
cell dose prior to TCRb rearrangement.
To assess the level of thymic T cell export occurring in vivo, the num-
ber of signal joint T cell receptor excision circles (sjTRECs), a
by-product of TCRa rearrangement, was quantiﬁed in sorted splenic
T cell populations at 16 weeks post-transplantation (Figure 2D). The
numbers of sjTRECs isolated from mice receiving the high and mid
doses were similar, implying that the transplanted cells had under-
gone comparable cell division after TCRa rearrangement, whichMolecular Therapy: Nucleic Acids Vol. 6 March 2017 3
Table 1. Latency andCellular Immunophenotype of LymphoidMalignancies
Wild-Type
Cell Dose Mouse
Latency
(Months) Immunophenotype
Thymus
Weight (g)a
5  104
50 12.7 CD3+ CD4– CD8– B220– ND
91 (313b) 9.5 CD3+ CD4+ CD8+ B220+ ND
97b 11.2 CD3+ CD4– CD8+ B220– 0.11
249 17.6 CD3– CD4– CD8– B220+ ND
5  103
133 9.0 CD3+ CD4+ CD8+ B220+ 0.18
137b 6.8 CD3– CD4+ CD8+ B220– 0.68
183 7.5 CD3+ CD4+ CD8+ B220– 0.56
189b 7.7 CD3– CD4+ CD8+ B220– 0.19
191b 8.0 CD3+ CD4+ CD8+ B220+ 0.48
192 10.0 CD3+ CD4+ CD8+ B220– 0.76
209b 9.1 CD3+ CD4+ CD8+ B220– 0.80
215 10.3 CD3– CD4+ CD8– B220– 0.29
250 10.9 CD3– CD4– CD8– B220+ ND
258 10.0 CD3+ CD4+ CD8+ B220– 0.56
ND, not macroscopically detectable.
aWild-type C57BL/6 thymus is 0.05 g ± 0.002 g (n = 20).
bWhole-genome massively parallel sequencing performed; m313 is the secondary recip-
ient of m91 leukemic blasts.
Molecular Therapy: Nucleic Acidsoccurs at the double-positive (DP) stage in the thymus. In contrast,
there was a modest, but statistically signiﬁcant, reduction in the num-
ber of sjTRECs present in splenocytes from mice transplanted with
the low dose of progenitors when compared with both the high and
mid cell doses. This is indicative of increased T cell expansion in
the cohort of mice receiving the low dose of gc-expressing progeni-
tors and is consistent with the observation of similar peripheral
T cell reconstitution when compared with the mid dose group
(Figure 2A).
Limiting Thymic Precursor Supply Affects the Size and
Composition of the Thymus
We next sought to investigate the size and composition of the thymo-
cyte population following transplantation. Thymocytes are classiﬁed
into distinct stages based on expression of cell-surface markers, the
earliest of which are DN for both CD4 and CD8. This DN population
contains four sub-stages (DN1–DN4) identiﬁed by the level of cell-
surface CD25 and CD44. Thymocytes then enter the DP stage where
they are positive for both CD4 and CD8 before becoming single pos-
itive (SP; positive for either CD4 or CD8). At 6 weeks post-transplan-
tation, for animals receiving either the high or low dose of wild-type
progenitor cells, the total number of thymocytes was signiﬁcantly
reduced when compared to age-matched wild-type control animals
not receiving bone marrow transplantation (Figure 3A). This demon-
strates that transplantation even of high doses of wild-type progeni-
tors leads to sub-physiological levels of thymocyte reconstitution.
The difference between the high and low wild-type treatment groups
was also signiﬁcant; notably, however, the difference in the total num-
ber of thymocytes between these groups was only 7-fold, despite the4 Molecular Therapy: Nucleic Acids Vol. 6 March 2017100-fold difference in the number of transplanted gc-expressing
cells capable of progressing past the DN2 stage, conﬁrmed by ﬂow cy-
tometry using Ly5.1 and Ly5.2 labeling to identify the gc-negative and
gc-positive populations, respectively (Figure S1), indicating increased
expansion in the low-dose cohort.
The contribution of DN, DP, and SP cells in the thymus was exam-
ined by ﬂow cytometry, which revealed a signiﬁcant reduction of
DP cells in transplanted animals, proportional to the number of avail-
able wild-type progenitors from the bone marrow (Figures 3B and
S2A). Interestingly, this was concomitant with a signiﬁcant increase
in the proportion of mature CD4+ and CD8+ SP cells, that also ex-
pressed CD3, in transplanted animals compared with wild-type
controls, potentially indicating an increased need for early T cells to
transition through the thymus (p < 0.01 for comparisons between
all groups). Examination of the DN compartment showed that the
proportion of cells in the DN1 stage was signiﬁcantly increased in an-
imals receiving the low dose of gc-progenitors compared both with
mice receiving the high progenitor cell dose and with wild-type con-
trol animals (Figures 3C and S2B). A signiﬁcant reduction was also
observed for cells at the DN3 stage in mice receiving the low dose
of gc-expressing progenitors.
The most evident difference between animals receiving the low dose
of gc-expressing progenitors and those receiving the high progenitor
dose or wild-type animals not receiving bone marrow transplantation
was in the fold changes of thymocyte cell numbers within the DN
niches. For the low-dose cohort, the ratio of DN2 to DN1 cells was
signiﬁcantly reduced (Figure 3D), possibly reﬂecting a rapid transi-
tion of cells from the DN2 niche, in an attempt to prevent lymphope-
nia in these animals. In striking contrast, there was a marked 6-fold
increase in the ratio of DN4 to DN3 cells in mice receiving the low
dose of gc-expressing progenitors, which may be indicative of a ho-
meostatic mechanism to maintain the peripheral compartment size.
It is possible that cells within the DN4 niche (i.e., negative for CD4,
CD8, CD25, and CD44) could include progenitor cells of non-T
cell lineages that reside in the thymus which may affect interpretation
of DN ratios. It should also be emphasized, despite the differences
observed in the relative proportion of each DN niche, particularly
for animals receiving the low progenitor cell dose compared to
wild-type control animals, that this is in concert with a marked reduc-
tion in the absolute number of cells in the thymus, and, therefore, all
DN niches are diminished.
Molecular Characterization of Leukemic Clones
Genomic DNA was isolated frommalignant blasts of affected animals
and qPCR performed using primers to detect wild-type gc sequence,
with wild-type sequence accounting for between 69.7% and 97.2% of
the genomic DNA sample and correlating with the majority of each
sample containing malignant cells. Importantly, this conﬁrmed that
all malignancies were derived from the transplanted gc+ wild-type
donor and not the gc-deﬁcient donor or recipient cell populations,
which is supported by the expression of T and/or B cell markers in
the samples (Table 1).
Figure 2. Immunological Reconstitution and T Cell Diversity under Conditions of Limiting Bone Marrow Progenitor Supply
(A) Totalwhite cell countsweredeterminedusingperipheral bloodsamples taken fromthe tail veinat16weekspost-transplantation.Subset analysiswasperformedbystainingwith
antibodies againstmurineCD2,CD3,CD45,B220, andNK1.1and flowcytometric analysis.Data showmean±SEM;n=32, 31, and30 for the high,mid, and lowwild-typedoses,
respectively. (B) Peripheral bloodwas taken frommice at 15weekspost-transplantation, andTCRVb repertoire analysiswasperformedbyqRT-PCR.Thepercentageof eachTCR
Vb family is indicatedwith results representing themean of triplicate values for each group (n = 3). (C) CDR3 spectratypes of TCR Vb 13-2, 16, and 19 families in reconstitutedmice
transplanted with each of the three wild-type cell doses as indicated. (D) Quantitation of sjTREC in purified T cell populations from the spleen, 15 weeks following transplantation.
Blue bars, high gc-expressing cell dose (5 105 cells); green bars, mid gc-expressing cell dose (5 104); red bars, low gc-expressing cell dose (5 103 cells).
www.moleculartherapy.orgWhole-genome sequencing (WGS) was performed on selected
leukemic clones that contained a high proportion (R75%) of
malignant cells (Figure 4; m97, m137, m189, m191, m209, and
m313) to identify potential common mutational signatures. Microar-
ray analysis was also performed on ﬁve of the six samples (the quality
of RNA for sample m137 was not sufﬁcient for analysis). Of the 407
mouse orthologs contained in the Sanger cancer consensus genes
database (http://cancer.sanger.ac.uk/census/), 14 (3.4%) displayed
expression levels that were altered >2-fold when compared to wild-
type thymocytes (Brca2, Card11, Ccnd1, Gnaq, Hmga1, Il21r, Itk,
Jazf1, Notch1, Nr4a3, Pdgfrb, Recql4, Rel, and Tfrc). All sequenced
samples except m313 (adoptive transfer recipient) showed evidenceof substantial copy number decreases on the X chromosome, in com-
parison to Sca1+ bone marrow progenitors. Also, substantial copy
number gains on chromosome 15 were shown to be common for
mice receiving the low dose of gc-positive progenitors (m137,
m189, m191, and m209). This evidence is in keeping with the data
of Martins et al., who had observed gains on chromosome 15.10 Inter-
estingly, one sample (m209) also displayed large copy number gains
on chromosome 14 (Figure 4).
Activating Notch1 mutations were identiﬁed by WGS in each of
the samples, comprising either a 50 deletion or mutations within the
sequence encoding the proline, glutamate, serine, and threonineMolecular Therapy: Nucleic Acids Vol. 6 March 2017 5
Figure 3. Thymic Size and Composition under
Conditions of Limiting Bone Marrow Progenitor
Supply
(A) Size of the thymocyte population at 6 weeks post-
transplantation in C57BL/6 control animals (black bar) or
mice receiving either the high (blue bar) or low-dose (red
bar) of gc-expressing progenitor cells. (B) Percentages of
early T cells within the thymus at 6 weeks post-trans-
plantation in age-matched controls and animals receiving
the high or low dose of gc-expressing progenitors; DN,
blue; DP, green; SP CD8+, red; SP CD4+, purple. (C)
Percentages of cells within the DN niche at 6 weeks post-
transplantation in age-matched controls and animals
receiving the high or low dose of wild-type progenitors;
DN1, darkest blue; DN2, mid blue; DN3, light blue; DN4,
dark blue. (D) Ratios of cells in the DN niches (DN2:DN1,
DN3:DN2, and DN4:DN3) at 6 weeks post-transplantation
in age-matched controls (black bars) and animals
receiving the high (blue bars) or low (red bars) dose of wild-
type progenitors. Values represent the mean ± SEM with
n = 7, 6, and 6 for age-matched controls and high and low
gc-expressing progenitor cell doses, respectively.
Molecular Therapy: Nucleic Acids(PEST) domain located in exon 34 (Figure 5A). Sanger sequencing
across the affected regions conﬁrmed these mutations and gene
expression proﬁling by microarrays identiﬁed Notch1 upregulation
in malignant samples (3.5-fold, false discovery rate [FDR] adjusted
p value = 0.012). Of the six samples investigated, ﬁve contained the
50 deletion and ﬁve contained a mutation in exon 34, with four of
the six samples carrying both lesions. We also observed exon 34 de-
letions in our previous study.5 Similar mutations have been identiﬁed
in leukemia samples generated under conditions of thymic progenitor
cell deprivation.10 To investigate the presence of activating mutations
in the Notch1 proto-oncogene in our other samples, DNA sequence
analysis was performed across the breakpoint of the 50 deletion as
well as the PEST, transactivation (TAD), or heterodimerization
(HD) domains. Further, activating Notch1 mutations (50 deletions
and/or PEST domain mutations) were identiﬁed in the remaining tu-
mors (those not subjected to WGS) from mice transplanted with the
low dose of gc-expressing progenitors (Table 2; Figures 5B and 5C).
The impact of activating mutations in Notch1 was investigated by us-
ing qRT-PCR directed at the downstream targets, c-myc, Dtx1, and
Hes1. In the malignant blasts examined (n = 5), elevated levels of these
transcripts were observed when compared to normal wild-type thy-
mocytes; c-myc, Dtx1, and Hes1 were found to be upregulated by
6.85 ± 1.80, 2.47 ± 0.54, and 2.78 ± 0.26-fold, respectively (data not
shown). Upregulation of Hes1 (9.78-fold, FDR = 0.021) and c-myc
(3.25-fold, FDR = 0.073) in malignant blasts was also detected by mi-
croarray analysis.
DISCUSSION
We have identiﬁed limiting bone marrow progenitor supply to the
thymus as an initiator of lymphoid malignancy in mice. Importantly,6 Molecular Therapy: Nucleic Acids Vol. 6 March 2017this oncogenic risk is cell dose dependent, occurs within cell dose
ranges that support immunological reconstitution, and does not
require the complete absence of progenitor cell migration from the
bone marrow as previously observed in thymic grafting studies,8,10
making this feature of our model unique. Based on existing evidence,
themechanismunderlying oncogenesis is theorized to have two critical
components. The ﬁrst is the induction of a transformation-prone self-
renewal phenotype in a subset of thymocytes as a homeostatic response
to an inadequate supply of progenitors from the bone marrow.7–9 The
second is reduced competitive pressure on this at-risk population for
thymic niche space from differentiation-committed thymocytes pro-
gressing through lymphoid ontogeny.10 The proposed combined effect
would be an increase in the number and residency time of transforma-
tion-prone thymocytes, leading to a correspondingly higher probability
of cells within this population being subject to oncogenic second hit
events, such as activating mutations in Notch1.
In an effort to phenocopy gene therapy for SCID-X1 in our model
system, mice were reconstituted with serially fewer wild-type bone
marrow progenitor cells, used as surrogates for gene-corrected cells,
against a background of gc-deﬁcient progenitors adjusted tomaintain
a constant total cell dose in all treatment groups. In this context, the
inverse correlation observed between the incidence of T-lymphoid
malignancy and wild-type progenitor cell dose is consistent with a
failure of gc-deﬁcient cells to progress to the point in T cell ontogeny,
the DN3 niche, where competitive pressure on tumor-prone self-
renewing thymocytes has been hypothesized to exert a tumor-sup-
pressive effect.10
When we initially observed T-lymphoid oncogenesis, independent of
insertional mutagenesis in our earlier gene therapy study in SCID-X1
Figure 4. Whole-Genome Sequence Analysis of Selected Lymphoid Malignancies
Circos plots representing six malignant genomes are shownwith notablemutations (somatic SNVs and InDels) compared to wild-type Sca1+ progenitors indicated. The three
circles in each plot, from outermost inward, represent the mouse chromosomes, copy number alterations (red dots >1.5-fold, green dots <0.5-fold), and structural re-
arrangements (rearrangement types are depicted with different colors, indicated under the bottom panel). Genes with SNV (red) and small InDels (black) are labeled on the
circos plots, except for mutations in Chr8 and Chr11 of m313 owing to space limitations. An asterisk indicates InDels identified in the PEST domain of Notch1.
www.moleculartherapy.orgmice,5 we favored replicative stress as a possible tumorigenic mecha-
nism. For this reason, an effort was made to examine the differing ef-
fects of limiting progenitor cell doses on the extent and location of the
homeostatic cellular expansion during T cell ontogeny by assessing
TCR diversity and number sjTREC in peripheral blood T cells,
although an analysis of whether there were differences in the percent-
ages of naive and memory peripheral T cells, with an increase in the
latter indicative of homeostatic proliferation under conditions of lym-
phopenia,13 was not performed. Despite 100-fold fewer cells capable
of progression past the DN2 stage of thymic ontogeny, and competent
for lymphoid ontogeny in the low-dose wild-type progenitor cell
treatment group, reduction in the resultant peripheral T cell compart-
ment size was only in the order of 2-fold. This is clearly indicative of
higher levels of cellular replication during T cell ontogeny in these an-
imals. While this represents a 50-fold change in the relative size of theinput progenitor and output peripheral T cell populations, the relative
difference in the absolute number of cell divisions required to achieve
this, in an exponentially expanding population, is much smaller.
Accepting that the dynamics of thymic homeostasis are complex,14,15
this argues against the oncogenic risk observed at limiting progenitor
cell doses being a simple function of the cumulative burden of somatic
mutations acquired during individual cell division events. Data from
TCR diversity and sjTREC analysis in peripheral blood and splenic
T cells, respectively, also provide similar arguments supporting
this point. Relatively well-preserved TCR diversity, in concert with
TREC-based evidence for a 2-fold replicative expansion of T cells
following TCRa rearrangement in mice receiving 100-fold fewer
gc-expressing progenitors, provides evidence of homeostatic expan-
sion both before and after the DP stage of T cell ontogeny. WhileMolecular Therapy: Nucleic Acids Vol. 6 March 2017 7
Figure 5. Molecular Analysis of Lymphoid Malignancies Observed under Conditions of Limiting Bone Marrow Progenitor Supply
(A) Schematic representation of murine Notch1 indicating the position of the 50 deletion (D50) and activating mutations in exon 34 affecting the PEST domain (triangles). The
numbers of malignancies with exon 34 mutations are indicated; white, frameshift deletions; gray, frameshift addition; black, single nucleotide substitution resulting in a
premature stop codon. The location of a cryptic promoter (exon 25) is designated by the arrow. (B) Graph showing the frequency and type of Notch1mutations (D50 and/or
PEST domain) identified in T cell malignancies at the low (n = 9) and mid (n = 3) wild-type progenitor cell doses. ND, not detected. (C) The Notch1 germline sequence flanking
exons 1 and 2 is indicated in the top row and samples, with evidence of N nucleotide addition (in lower case), shown below. Sequences in red rectangles are heptamer-
(CACAGTG) or nonamer-like (ACAAAAACC) motifs separated by 12- or 23-bp spacers and asterisks indicate canonical nucleotide residues.53 Arrows designate the sites of
Rag-mediated DNA breakage.
Molecular Therapy: Nucleic Acidsthis supports a 50-fold relative expansion prior to, and a 2-fold expan-
sion after the DP stage, in an exponentially growing population, the
difference in the absolute number of cell divisions occurring before
and after the DP stage is likely to be relatively small. Further analyses,
including whether there is increased proliferation of wild-type pro-
genitors, compared to the immunodeﬁcient populations, or a greater
number of early thymic progenitors (ETPs) would contribute to the
understanding of the extent and location of the homeostatic cellular
expansion during T cell ontogeny in our model. Early thymic progen-
itors, identiﬁed by high levels of cKit on their surface (cKithigh cells),
have been shown to support long-term thymopoiesis in intrathymic
transplantation studies.13,16 If cell division itself was a strong risk fac-
tor for transformation, then one would expect a high proportion of
such events to occur in more mature T cells, which is unsupported
by existing evidence.7–11
When considering the possible relevance of these murine data to
the oncogenic mechanisms operative in early human SCID-X1 gene
therapy trials, it is important to emphasize that murine cells are
inherently more transformation-prone than human cells,17 and to
our knowledge there is no evidence to suggest that limiting thymic
precursor supply in humans carries oncogenic risk through the induc-
tion of thymocyte self-renewal. Indeed, based on clinical experience
in allogeneic stem cell transplantation for SCID phenotypes including8 Molecular Therapy: Nucleic Acids Vol. 6 March 2017SCID-X1, Qasim et al. have argued against oncogenic risk being asso-
ciated with a lack of bone marrow progenitor supply to the human
thymus.18 They point to the absence of reports of T cell malignancy
in patients with long-term thymopoiesis, despite single-lineage donor
T cell recovery, which is considered indicative of thymic, but not bone
marrow engraftment.
A further important point is that oncogenesis in early human clinical
trials, using conventional g-retroviral vectors to treat SCID-X1,
chronic granulomatous disease (CGD),19 and Wiskott-Aldrich syn-
drome (WAS)20 invariably involved insertional mutagenesis, while
oncogenic adverse events have not subsequently been observed
with SIN g-retroviral or SIN lentiviral vectors lacking strong viral
enhancer-promoter elements. Nevertheless, we argue that insertional
proto-oncogene activation in human hematopoietic progenitors, as
reported in early SCID-X1 trials, is likely capable of inducing trans-
formation-prone thymocytes. This is supported by the observation
that deliberate Lmo2 overexpression in mice can induce thymocyte
self-renewal without a homeostatic drive being exerted by a limiting
or absent progenitor supply.11 Once such cells arise in the human
thymus, albeit by an iatrogenic mechanism, it is plausible that
gc-deﬁcient human thymic progenitors, akin to their murine coun-
terparts, also fail to exert a tumor suppressor effect through compet-
itive pressure. Thus, the parallels of our ﬁndings, and those of
Table 2. Summary of Notch1 Mutations Identified in Lymphoid
Malignancies
Wild-Type
Cell Dose Mouse
50 Deletion
(D50) Exon 34 Mutationa
5  104
50 ND ND
91 ND ND
97 yes ND
249 ND ND
5  103
133 yes G > T 7172, insertion TTAC 7173
137 yesb insertion CA 7283, G > C 7284
183 yesb C > T 7345
189 yes G > C 7172, insertion ACCT 7173
191 ND G > A 7284, insertion AATCGAAGGGC 7285
192 yes ND
209 yes insertion AGTCTGAAGA 7362
215 ND insertion T 7146
250 ND ND
258 yes deletion CA 7476
NAc 313 yes insertion CA 7283, G > C 7284
ND, not detected by sequencing amplicon clones; NA, not applicable.
aFrameshift mutations all result in the introduction of a premature stop codon and asso-
ciated loss of the PEST domain; indicated position is relative to GenBank accession
AB100603.1. Mutations were not identiﬁed in the HD or TAD domains.
bTwo break points were identiﬁed.
cm313 is the secondary recipient of m91 leukemic blasts.
www.moleculartherapy.orgpreviously reported thymic transplant studies, to the human gene
therapy experience occurs once the cells acquire a capacity for self-
renewal, induced by either limiting precursor supply or by proto-
oncogene activation. This also provides an alternative explanation
for the suggested oncogenicity of gc itself that has been the topic of
much debate.21,22
An intriguing question arising from the tumor suppressor hypothesis
is whether there might be disease-speciﬁc differences among disor-
ders affecting T cell ontogeny in the capacity of thymocytes to exert
tumor-suppressive effects through cell competition. For example, in
gene therapy trials for ADA-SCID, using conventional g-retroviral
vectors to transduce bone-marrow-derived CD34+ cells, there have
been no reports of T cell leukemia, despite the frequent observation
of integration events in LMO2 and other proto-oncogene loci.23 Un-
like gc-deﬁcient thymocytes, which fail to progress beyond the DN2
thymic niche, ADA-deﬁcient thymocytes are able to progress through
thymic ontogeny when the thymic microenvironment is sufﬁciently
metabolically detoxiﬁed,24 thereby providing a possible tumor sup-
pressor effect in more distal thymic niches by competing with trans-
duced cells carrying insertional proto-oncogene activation events
(Figure 6). While alternative hypotheses exist to explain the differing
risk of oncogenesis in early gene therapy trials for SCID-X1 and
ADA-SCID, none provide a unifying conceptual framework. For
SCID-X1 these include evidence for cooperativity between Lmo2
and gc expression in the thymus with double transgenic miceshowing accelerated development of T cell malignancy, strikingly in
association with Notch1 mutations.25 For ADA-SCID, these include
the possibility that the progenitors transduced in bulk CD34+ popu-
lations might be more differentiated than for SCID-X1, and that the
level of vector-encoded ADA expression might be insufﬁcient to sup-
port the development of a T cell leukemic phenotype, which has been
shown to be associated with increased ADA expression.26 Another
notable difference between these two gene therapy trials was the
use of sub-ablative busulfan conditioning in ADA-SCID patients,
which is known to increase the level of bone marrow engraftment.27
It is therefore conceivable that increased bone marrow engraftment
may lead to increased thymic seeding with a resultant reduction in
oncogenic risk. Increasing the level of myeloablative condition in
our model might also reduce the incidence of malignancy for a given
cell dose. A further challenge is to reconcile the concept of cell compe-
tition as a tumor suppressor mechanism in the thymus with the
occurrence of T cell leukemias in a gene therapy trial for Wiskott-
Aldrich syndrome (WAS) using a conventional g-retroviral vector.20
Six of ten treated patients developed T-ALL with dominant LMO2
clones identiﬁed in each case. Several of the leukemias also had
secondary mutations in the proto-oncogenes TAL1 and LYL1, both
of which are known to be associated with T-ALL. Similar to ADA-
SCID, there is no absolute block to T cell ontogeny in the thymus
in WAS, although abnormalities of T cell development have been
implicated in this condition.28–30 Of particular relevance, the WAS
protein (WASP) has been shown to be important for double-negative
to double-positive cell transition that may partly be explained by
reduced cycling of DN3 cells. Further, it has been suggested that in
the absence of WASP, the decreased migratory responses and
increased percentage of single positive cells implies retention of these
cells in the thymus.29 It therefore remains plausible that this could
result in reduced competitive pressure on thymocytes rendered pre-
leukemic by insertional proto-oncogene activation. Data derived
from our model are certainly consistent with this possibility given
our demonstration that lymphoid oncogenesis does not require a
complete block in bone marrow progenitor supply and, at least in
mice, is observed at wild-type progenitor cell doses that are sufﬁ-
ciently high to reconstitute the peripheral T cell compartment.
Ultimately the hypothesis that ADA and WAS protein-deﬁcient
thymocytes have differing capacities to act as tumor suppressors in
the thymus, through cellular competition, requires experimental
evaluation and could be addressed in the model system we describe
in the current report using gc-deﬁcient cells.
Ultimately, despite evidence that insertional proto-oncogene activa-
tion was necessary, but not sufﬁcient, for development of T cell leu-
kemias in early gene therapy trials for SCID-X1, the second hit events
required for transformation, which we hypothesize are suppressed
by cellular competition, show considerable similarity in mice and
humans, most notably activating mutations in the PEST domain of
NOTCH1.3,4 These, predominantly frameshift, mutations result in
the production of a truncated protein and persistent activation of
Notch1 downstream targets5,31,32 and are consistent with those iden-
tiﬁed in our previous gene therapy model.5 Interestingly, in contrastMolecular Therapy: Nucleic Acids Vol. 6 March 2017 9
Figure 6. Hypothetical Models of Competitive and
Impaired Replacement in gc-Deficient Mice and
Human Clinical Trials of ADA-SCID and SCID-X1,
where the Acquisition of an At-Risk Phenotype May
Lead to Malignant Transformation
(A) The thymus is continuously supplied from the bone
marrow when transplanted with a high dose of wild-type
cells, thereby replacing thymus-resident progenitor cells.
When a low dose of wild-type cells are transplanted;
however, there is reduced competition possibly leading to
self-renewal of thymus-resident progenitors, increased
residence time in the thymus, and the potential to acquire
additional genomic mutations such as those observed in
Notch1. (B). In ADA-SCID, cells containing deleterious in-
tegrations migrate out of the thymus by normal cellular
replacement, because cells that are not gene-modified are
capable of progressing past the DN2 niche. For SCID-X1,
however, cells containing similar integrations in LMO2may
have self-renewal potential. These cells could then be re-
tained in the thymus for extended time periods because of
reduced progenitor cell migration (because cells that have
not been gene-corrected are unable to progress past the
DN2 niche due to a lack of interleukin-7 [IL-7] signaling) and
may acquire additional genetic lesions in some patients.
Molecular Therapy: Nucleic Acidsto the ﬁndings of Martins et al.,10 mutations in the HD or TAD do-
mains were not present in our samples. This is likely due to theNotch1
50 deletion being functionally similar to a HD mutation (see below);
thus, the presence of a 50 deletion and HD mutation in the same
cell would be mechanistically redundant.33 Finally, consistent with
the strong association of Notch1 mutations and cases of T cell leuke-
mia and lymphoma34 in the two malignancies not expressing T cell-
surface markers (m249 and m250), Notch1 mutations could not be
detected by sequencing amplicon clones. This was in contrast to ob-
servations by Martins et al., where all leukemias had an immature
CD8 single-positive (ISP)/double-positive (DP)-like surface pheno-
type10 and possibly reﬂect inherent differences between these two10 Molecular Therapy: Nucleic Acids Vol. 6 March 2017models, notably the source of thymic progeni-
tors being either whole thymus or, in our model,
more immature bone marrow progenitor cells.
In samples with the 50 deletion, an aberrant
Notch1 mRNA initiated from a cryptic pro-
moter in exon 25 produces an active intracel-
lular Notch1 protein that is independent of
ligand binding and g-secretase cleavage35–37
and therefore constitutively expressed (Fig-
ure 5A). These mutations have been shown to
result from illegitimate V(D)J recombination36
and, in our study, may have arisen from a failure
of cells to exit the thymus as a result of reduced
progenitor cell supply. Notably, although 50 de-
letions inNOTCH1were not identiﬁed in SCID-
X1 patient samples, they did contain deletions in
the tumor suppressor gene locus cyclin-depen-dent kinase inhibitor 2A (CDKN2A), also shown to be the conse-
quence of aberrant V(D)J recombination;33 however, similar Cdkn2a
deletions were not found in the six tumor genomes analyzed by WGS
in this study. Further evidence of illegitimate V(D)J recombination
was identiﬁed in our model by whole-genome sequencing, where
both a/b and g/d recombination events were present in all six tumor
genomes analyzed (data not shown). This is in keeping with the
observation that the T-ALL that developed in some patients in the
SCID-X1 trials arose from both the a/b and g/d T cell populations.
In summary, our studies support the role of regenerating thymic pre-
cursors in the thymus leading to further genetic abnormalities that
www.moleculartherapy.orgpredispose to cancer. These ﬁndings help explain the differences in
cancer risk in diseases treated with gene therapy based on the relative
size of the thymic precursor pool and the need for regenerative thymic
clones that are predisposed to malignant transformation. Although
there is currently no evidence that limiting thymic precursor supply
is a risk factor for lymphoid malignancy in humans, our data provide
a compelling conceptual framework that could explain why T cell
leukemia was observed in early SCID-X1 trials but not in ADA-
SCID patients, despite both groups containing integrations near
proto-oncogenes such as LMO2.
MATERIALS AND METHODS
Animals
IL2RG/mice12 were obtained from The Jackson Laboratory, gc/
Rag2/ mice were kindly provided by Professor Stephen Nutt
(Walter and Eliza Hall Institute, Parkville, Australia), and C57BL/6
mice were obtained from the Animal Resources Centre (ARC). All
experimental procedures were approved by the Animal Ethics
Committee of the Children’s Medical Research Institute and The
Children’s Hospital at Westmead.
Progenitor Cell Isolation and Transplantation
Recipient gc/Rag2/ mice were exposed to sublethal (6 Gy)
irradiation using a Gammacell 40 Exactor (MDS Nordion). Bone
marrow was harvested from 8- to 10-week-old IL2RG/, C57BL/6,
or C57BL/6 Ly5.1 congenic mice, and Sca1+ progenitor cells were iso-
lated using the EasySep SCA1 positive selection kit (STEMCELL
Technologies), resuspended in 200 mL RPMI 1640 medium (Life
Technologies) and injected intravenously into recipient mice via the
tail vein.
Analysis of TCR Repertoire and CDR3 Spectratyping
At 15 weeks post-transplantation, individual TCR Vb families in pe-
ripheral blood were detected using qRT-PCR and primers speciﬁc for
the TCR b chain.38 All analyses were performed in triplicate as previ-
ously described.39 The TCRVb repertoire diversity of the six most
highly represented TCR Vb families was subsequently analyzed by
CDR3 spectratyping as outlined previously.38
Quantitation of Signal Joint T Cell Receptor Excision Circles
At 16 weeks post-transplantation, T cells from reconstituted mice
were separated using the EasySep Mouse CD90.2/Thy 1.2 Positive Se-
lection Kit (STEMCELL Technologies) and genomic DNA isolated
using the Gentra Puregene cell kit (QIAGEN). Signal joint T cell
excision circles (sjTREC) were detected by using real-time qPCR
with the following primer and probe set; forward 50-CATTGCCT
TTGAACCAAGCTG-30; reverse, 50-TTATGCATAGGGTGCAG
GTG-30; probe 50-FAM-CGGCAGGGTTTTTGTAAAGGTGCTC
ACTT-QSY-30.40 Reactions were performed on a Rotor-Gene 6000
(QIAGEN), and the number of sjTRECwithin each sample was deter-
mined by using the comparative Ct method and a sample containing a
known number of sjTREC copies, diluted in murine 3T3 cell genomic
DNA. The constant gene segment of the TCRA gene (Ca) was used to
compensate for variations in input DNA with the following primerand probe set: forward 50-TGACTCCCAAATCAATGTG-30; reverse,
50-GCAGGTGAAGCTTGTCTG-30; probe 50-FAM-TGCTGGACAT
GAAAGCTATGGA-QSY-30.41
Flow Cytometric Analysis
Cells from the bone marrow, thymus, spleen, liver, and peripheral
blood were stained and analyzed on a FACSCanto (BD Biosciences)
running FACSDiva (v.6.1.3) and FlowJo (v.7.6.1, FlowJo LLC) soft-
ware. Lymphocytes were identiﬁed and gated based on their for-
ward-scattered light (FSC) and side-scattered light (SSC) proﬁles.
Cell suspensions were treated with ACK lysis buffer (150 mmol/L
NH4Cl, 10 mmol/L KHCO3, and 0.1 mmol/L disodium EDTA) and
then stained with the following conjugated antibodies: B220-APC-
Cy7 (BD Biosciences), CD2-FITC (BD Biosciences), CD3ε-PE (BD
Biosciences), CD3ε-Alexaﬂore 647 (BD Biosciences), CD4-FITC
(Caltag Laboratories), CD8a-APC (Caltag Laboratories), CD8a-Alex-
aﬂore 647 (BD Biosciences), CD25-FITC (BD Biosciences), CD44-PE
(BD Biosciences), CD45-APC (BD Biosciences), Ki-67-FITC (BD
Biosciences), Ly5.1-PerCP-Cy5.5 (BD Biosciences), Ly5.2-PerCP-
Cy5.5 (BD Biosciences), NK1.1-APC (Caltag Laboratories), and
Sca1-Alexaﬂore 647 (BD Biosciences).
Histology
Tissue was dissected from C57BL/6 control or transplanted gc/
Rag2/ recipient mice and ﬁxed in 10% buffered formalin (Sigma-
Aldrich). Parafﬁn-embedded sections (5 mm) were stained with
H&E and evaluated by light microscopy. Images were captured
from a Zeiss Axio Imager.A1 Microscope (Carl Zeiss MicroImaging)
using a Spot enhanced camera (Diagnostic Instruments, SciTech)
running Spot Software (v.4.0.1).
qPCR to Determine Leukemic Origin
To determine whether malignancies were donor or recipient in
origin, genomic DNA was isolated using the Gentra Puregene
cell kit and qPCR performed using primers to either the hu-
man gc (50-CTTTATTGATAACGATCTATATCCCTCACCC-30
and 50-CTCCACTCTGCAGAGTCTATGGAATCC-30) or bacte-
rial neomycin phospho-transferase (50-CTTGGGTGGAGAGGCTA
TTC-30 and 50-AGGTGAGATGACAGGAGATC-30) gene. Reactions
were performed on a RotorGene 6000 (QIAGEN) using the
QuantiTect SYBR Green PCR kit (QIAGEN) and standardized using
primers to the murine titin gene (50-AAAACGAGCAGTGACG
TGAGC-30 and 50-TTCAGTCATGCTGCTAGCGC-30) by the
comparative Ct method.
Primary Sequence Analysis and Variation Detection
Genomic DNA from six lymphoid tumors and one control sample of
C57BL/6 Sca1+ progenitor cells were sequenced at the Beijing Geno-
mics Institute (BGI), using HiSeq2000. Whole-genome sequencing
was achieved to 30 times coverage and a comparative analysis
between the control sample and the tumors, to call tumor-speciﬁc
somatic single nucleotide variants (SNVs), somatic copy number
variations (CNVs), short insertions/deletions (InDels), and structure
variant (SV) mutations, was performed. BGI’s cancer genomicsMolecular Therapy: Nucleic Acids Vol. 6 March 2017 11
Molecular Therapy: Nucleic Acidsbioinformatics pipeline was applied for sequencing analysis and
variation detection (http://www.bgitechsolutions.com/). Paired-end
reads were aligned by Burrows-Wheeler aligner (BWA)42 to the
mouse mm9 reference genome. All BAM ﬁles were processed to iden-
tify duplicates using the Picard MarkDuplicates tool from the Broad
Institute. SNVs were detected using VarScan,43 InDels were called
by SAMtools,44 CNVs were called by BGI’s proprietary method
CNV_Detection, and SVs were called by CREST.45 Copy number
ratios <0.5 were considered as deletions and >1.5 as ampliﬁcations.
ANNOVAR software46 was used to annotate the variant results.
The Integrative Genomics Viewer (IGV) 2.347 was used to visually
inspect sequence reads. BAM ﬁles and associated metadata in XML
format have been uploaded to the European Nucleotide Archive
(ENA; http://www.ebi.ac.uk/ena) under the study identiﬁcation
number PRJEB8006.Gene Expression Arrays
Total RNA for expression analysis was isolated using the RNeasy
Mini Kit (QIAGEN), and transcriptome proﬁling was performed
by The Ramaciotti Centre for Gene Function Analysis (University
of New South Wales). Brieﬂy, total RNA samples (500 ng/sample)
were ampliﬁed and labeled according to the manufacturer’s in-
structions (Affymetrix). Ampliﬁed RNA was quantiﬁed using a
NanoDrop (Thermo Scientiﬁc) and distribution of the ampliﬁed
material was analyzed in a 2100 Bioanalyzer (Agilent). Ampliﬁed
cRNA was hybridized onto Affymetrix mouse 2.1 gene arrays;
the arrays were scanned and expression measurements extracted
using the Affymetrix Expression Console v.1.3 software. Microar-
ray data have been deposited at ArrayExpress (http://www.ebi.ac.
uk/arrayexpress/) under the accession number E-MTAB-3159.Gene Expression Data Analysis
Robust Multi-array Average (RMA) was applied to normalize the
expression data,48 and the remaining analysis was carried out using
Bioconductor package49 in the R statistical language 3.01. Empirical
Bayes statistics for differential expression were calculated using
limma 3.16.6.50 p values were adjusted by Benjamini & Hochberg’s
method to account for multiple test correction.51 Genes with expres-
sion changeR2-fold and adjusted p value (FDR)%0.05 were consid-
ered as differentially expressed.Identification of Notch1 Gene Mutations and Structural
Variations
Mutations within the PEST, TAD, or HD domains of Notch1 were
identiﬁed by sequencing PCR products ampliﬁed using Pfu DNA po-
lymerase (Promega). Primers spanning exons 26, 27, and 34, where
the HD, TAD, and PEST domains are located, are described else-
where.31 The presence of structural variations in Notch1 identiﬁed
by WAS was conﬁrmed by PCR ampliﬁcation using Phusion high-ﬁ-
delity DNA polymerase (New England Biolabs) and primers adjacent
to the 50 and 30 break points (50- CAGTCAGGAGTGGTGGATCC-30
and 50-GGCTTGGTCTAGTGCTCCTG-30). In cases where the PCR
product contained more than one amplicon, the PCR product was12 Molecular Therapy: Nucleic Acids Vol. 6 March 2017cloned into pGEM-T Easy (Promega), and the sequence of individual
clones was determined.
qRT-PCR for Notch1 Downstream Targets
Total RNA was extracted using the RNeasy mini kit (QIAGEN) from
lymphoblastic cells or from wild-type thymocytes and cDNA synthe-
sized from 1 mg total RNA by using the Superscript III ﬁrst-strand
synthesis Supermix kit (Life Technologies). To determine whether
mutations in Notch1 affected expression of downstream target
genes, qRT-PCR was performed on a RotorGene 6000 using c-myc
(50-CTGTTTGAAGGCTGGATTTCCT-30 and 50-CAGCACCGA
CAGACGCC-30), Dtx1 (50-TGCCTGGTGGCCATGTACT-30 and
50-GACACTGCAGGCTGCCATC-30), and Hes1 (50-AAGACGG
CCTCTGAGCACA-30 and 50-CCTTCGCCTCTTCTCCATGAT-30)
primers52 using the Brilliant III Ultrafast SYBR green QPCR master
mix (Agilent Technologies). Expression levels were standardized
using primers to the b-actin gene (50- CTAGACTTCGAGCAGG
AGATGGC-30 and 50- TCTGCATCCTGTCAGCAATGCC-30) by
the comparative Ct method.
Statistical Analysis
Results were analyzed by the Wilcoxon rank-sum (Mann-Whitney)
(http://www.socscistatistics.com/tests/mannwhitney/default2.aspx)
or Fisher’s exact test (http://www.graphpad.com/quickcalcs/
contingency1.cfm). For comparison of population survival, cohorts
of mice were evaluated using Kaplan-Meier analysis (GraphPad
Prism v.5.04). Values represent the mean ± SEM and results
considered signiﬁcant when p < 0.05.
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